As a result of the COVID 19 outbreak, Avrobio reported that they have halted dosing new patients in clinical trials of its gene therapy candidates. including a Phase 1/2 study testing AVR-RD-02 in people with Gaucher disease type 1.
Avrobio’s CEO and President, Geoff MacKay, said in a press release that their priority during these times is the health of their employees, their patients and their communities, and the employees of their clinical sites, partners, and vendors.
He adds that they will continue to support patient identification in North America and Australia as the global healthcare community continues to fight against the COVID 19 virus.
MacKay adds that his company is continuing to monitor “this rapidly evolving situation” for its potential impact on both our clinical trial programs and business generally.”